Finasteride in Benign Prostatic Hyperplasia [2] (multiple letters)

New England Journal of Medicine

Volumn 350, Issue 13, 2004, Pages 1359-1361

  Wysowski, Diane K ^a   Farinas, Evelyn ^a   Verhamme, Katia M C ^b   Bosch, Ruud J L H ^b   Sturkenboom, Miriam C J M ^b   Roehrborn, Claus G ^c  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXAZOSIN; DUTASTERIDE; FINASTERIDE; PROSTATE SPECIFIC ANTIGEN; ENZYME INHIBITOR; STEROID 5ALPHA REDUCTASE;

BREAST CARCINOMA; CANCER RISK; CANCER SCREENING; CLINICAL TRIAL; CONFIDENCE INTERVAL; DRUG INDICATION; GYNECOMASTIA; HIGH RISK POPULATION; HUMAN; INCIDENCE; LETTER; MASTECTOMY; ORGAN SIZE; PRIORITY JOURNAL; PROSTATE; PROSTATE HYPERTROPHY; RETROSPECTIVE STUDY; RISK ASSESSMENT; TREATMENT OUTCOME; URINE RETENTION; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; MALE; NOTE; UNITED STATES;

BREAST NEOPLASMS, MALE; ENZYME INHIBITORS; FINASTERIDE; HUMANS; MALE; PROSTATIC HYPERPLASIA; TESTOSTERONE 5-ALPHA-REDUCTASE; UNITED STATES;

EID: 12144290895     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMc045013     Document Type: Letter

References (0)